The acute and long-lasting side effects of modern multimodal tumour therapy significantly
impair quality of life and survival of patients afflicted with malignancies. The key components …

This review discusses current research on acute paediatric leukaemia, the leukaemic bone
marrow (BM) microenvironment and recently discovered therapeutic opportunities to target …

The prognosis for B-cell precursor acute lymphoblastic leukemia patients with Mixed-
Lineage Leukemia (MLL) gene rearrangements (MLLr BCP-ALL) is still extremely poor …

Adult patients with relapsed B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have
a dismal prognosis. To improve pharmacotherapy, we analyzed induction of apoptosis by …

The outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
has greatly improved in the tyrosine kinase inhibitor (TKI) era and is moving to a chemo-free …

Dysregulation of the intrinsic BCL-2 pathway-mediated apoptosis cascade is a common
feature of hematological malignancies including acute B-lymphoblastic leukemia (B-ALL) …

Aberrant PI3K/AKT signaling is a hallmark of acute B-lymphoblastic leukemia (B-ALL)
resulting in increased tumor cell proliferation and apoptosis deficiency. While previous AKT …

Venetoclax, a small molecule inhibitor of BCL‐2, has demonstrated efficacy in treating acute
leukemias and has been recommended as one of the first‐line anti‐leukemia therapies …

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is a high-risk
disease subtype with a dismal prognosis. Inhibiting BCR-ABL kinase alone is insufficient to …

Central nervous system leukemia (CNSL) is a prominent infiltration reason for therapy failing
in acute leukemia. Recurrence rates and the prognosis have alleviated with current …